Document is current
Any future updates will be listed below
-
Authors
Barisic, Stefan https://orcid.org/0000-0003-4273-2907
Brahmbhatt, Elizabeth M
Cherkasova, Elena
Spear, Timothy T
Savani, Ujjawal
Pierre, Stephanie
Scurti, Gina M
Chen, Long
Igboko, Muna
Nadal, Rosa
Zeng, Gang
Parry, Gordon
Stroncek, David F
Highfill, Steven
Dalheim, Annika V
Reger, Robert
Nishimura, Michael I
Childs, Richard W
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03354390 at ClinicalTrials.govnct03354390 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
https://doi.org/10.1200/jco.2023.41.16_suppl.2549
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus
https://doi.org/10.1136/jitc-2024-009147
nct03354390 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
https://doi.org/10.1200/jco.2023.41.16_suppl.2549
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus
https://doi.org/10.1136/jitc-2024-009147
nct03354390 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
https://doi.org/10.1200/jco.2023.41.16_suppl.2549
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus
https://doi.org/10.1136/jitc-2024-009147
Documents that mention this clinical trial
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
https://doi.org/10.1200/jco.2023.41.16_suppl.2549
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus
https://doi.org/10.1136/jitc-2024-009147
-
Funding
Funding for this research was provided by:
Division of Intramural Research (1ZIAHL002345)
Dr. Ralph and Marian Falk Medical Research Trust (N/A)
T-cure Bioscience (N/A)
Dean R. O’Neill Renal Cell Cancer Research Fund (N/A)
- License Information
